ArticleThe oncologist2015
Genomic classifier ColoPrint predicts recurrence in stage II colorectal cancer patients more accurately than clinical factors.
Open access · bronzeAbstract read
In one paragraph
Article in The oncologist, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers.
0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed
8.4field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
74 citing papers in PubMed, 132 citations in OpenAlex.
- Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer.The New England journal of medicine · 2022Trial
- Article
- Multi Omics Integration in Colorectal Cancer: From Molecular Insights to Precision Oncology.Cancers · 2026Review
- A machine learning-based transcriptomic signature for predicting tumor recurrence after curative resection in T1 colorectal cancer: a retrospective multicenter cohort study (The Tw1CE trial).International journal of surgery (London, England) · 2026Article
- Clinical value of the novel inflammatory-nutritional marker PALR in predicting early postoperative recurrence of colorectal cancer.Discover oncology · 2025Article
- The prognostic potential of RNA in stage II colon cancer: Insights from a screened multicenter population-based cohort study.International journal of cancer · 2025Article
- An immune infiltration-based risk scoring system for prognostic stratification in colorectal adenocarcinoma.Ecancermedicalscience · 2025Article
- Stool and blood biomarkers for colorectal cancer management: an update on screening and disease monitoring.Molecular cancer · 2024Review
- The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine.Cancer discovery · 2024Article
- Article
- Unraveling the role of tumor sidedness in prognosis of stage II colon cancer.Gastroenterology report · 2024Article
- Prognostic models for colorectal cancer recurrence using carcinoembryonic antigen measurements.Frontiers in oncology · 2024Article
- An invasion front gene expression signature for higher-risk patient selection in stage IIA MSS colon cancer.Frontiers in oncology · 2024Article
- Integrating bulk and single-cell data to predict the prognosis and identify the immune landscape in HNSCC.Journal of cellular and molecular medicine · 2024Article
- Development and validation of an individualized gene expression-based signature to predict overall survival of patients with high-grade serous ovarian carcinoma.European journal of medical research · 2023Article
- Spatial tumour gene signature discriminates neoplastic from non-neoplastic compartments in colon cancer: unravelling predictive biomarkers for relapse.Journal of translational medicine · 2023Article
- Principles of Molecular Utility for CMS Classification in Colorectal Cancer Management.Cancers · 2023Review
- Development of novel DNAJB6-KIAA1522-p-mTOR three-protein prognostic prediction models for CRC.Translational oncology · 2023Article
- Development and validation of postoperative circulating tumor DNA combined with clinicopathological risk factors for recurrence prediction in patients with stage I-III colorectal cancer.Journal of translational medicine · 2023Article
- A methylation-based prognostic signature in stage II colorectal patients: Considerations for clinical adoption.Journal of the National Cancer Institute · 2023Article
14 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 8 institutions in 6 countries.
Scott KopetzDepartments of Gastrointestinal Medical Oncology and Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Vall d'Hebron University Hospital and Institute of Oncology, Universitat Autònoma de Barcelona, Barcelona, Spain; Department of Surgery, Klinikum Rechts der Isar, Technische University, Munich, Germany; Institut Català d'Oncologia, IDIBELL L'Hospitalet de Llobregat, Barcelona, Spain; Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, Barcelona, Spain; Department of Surgery, Medical University of Vienna, Vienna, Austria; Department of Surgery, University of Ferrara, Ferrara, Italy; Agendia NV, Amsterdam, The Netherlands; Agendia Inc., Irvine, California, USA skopetz@mdanderson.org.
Josep TaberneroDepartments of Gastrointestinal Medical Oncology and Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Vall d'Hebron University Hospital and Institute of Oncology, Universitat Autònoma de Barcelona, Barcelona, Spain; Department of Surgery, Klinikum Rechts der Isar, Technische University, Munich, Germany; Institut Català d'Oncologia, IDIBELL L'Hospitalet de Llobregat, Barcelona, Spain; Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, Barcelona, Spain; Department of Surgery, Medical University of Vienna, Vienna, Austria; Department of Surgery, University of Ferrara, Ferrara, Italy; Agendia NV, Amsterdam, The Netherlands; Agendia Inc., Irvine, California, USA.
Robert RosenbergDepartments of Gastrointestinal Medical Oncology and Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Vall d'Hebron University Hospital and Institute of Oncology, Universitat Autònoma de Barcelona, Barcelona, Spain; Department of Surgery, Klinikum Rechts der Isar, Technische University, Munich, Germany; Institut Català d'Oncologia, IDIBELL L'Hospitalet de Llobregat, Barcelona, Spain; Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, Barcelona, Spain; Department of Surgery, Medical University of Vienna, Vienna, Austria; Department of Surgery, University of Ferrara, Ferrara, Italy; Agendia NV, Amsterdam, The Netherlands; Agendia Inc., Irvine, California, USA.
Zhi-Qin JiangDepartments of Gastrointestinal Medical Oncology and Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Vall d'Hebron University Hospital and Institute of Oncology, Universitat Autònoma de Barcelona, Barcelona, Spain; Department of Surgery, Klinikum Rechts der Isar, Technische University, Munich, Germany; Institut Català d'Oncologia, IDIBELL L'Hospitalet de Llobregat, Barcelona, Spain; Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, Barcelona, Spain; Department of Surgery, Medical University of Vienna, Vienna, Austria; Department of Surgery, University of Ferrara, Ferrara, Italy; Agendia NV, Amsterdam, The Netherlands; Agendia Inc., Irvine, California, USA.
Víctor MorenoDepartments of Gastrointestinal Medical Oncology and Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Vall d'Hebron University Hospital and Institute of Oncology, Universitat Autònoma de Barcelona, Barcelona, Spain; Department of Surgery, Klinikum Rechts der Isar, Technische University, Munich, Germany; Institut Català d'Oncologia, IDIBELL L'Hospitalet de Llobregat, Barcelona, Spain; Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, Barcelona, Spain; Department of Surgery, Medical University of Vienna, Vienna, Austria; Department of Surgery, University of Ferrara, Ferrara, Italy; Agendia NV, Amsterdam, The Netherlands; Agendia Inc., Irvine, California, USA.
Thomas Bachleitner-HofmannDepartments of Gastrointestinal Medical Oncology and Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Vall d'Hebron University Hospital and Institute of Oncology, Universitat Autònoma de Barcelona, Barcelona, Spain; Department of Surgery, Klinikum Rechts der Isar, Technische University, Munich, Germany; Institut Català d'Oncologia, IDIBELL L'Hospitalet de Llobregat, Barcelona, Spain; Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, Barcelona, Spain; Department of Surgery, Medical University of Vienna, Vienna, Austria; Department of Surgery, University of Ferrara, Ferrara, Italy; Agendia NV, Amsterdam, The Netherlands; Agendia Inc., Irvine, California, USA.
Giovanni LanzaDepartments of Gastrointestinal Medical Oncology and Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Vall d'Hebron University Hospital and Institute of Oncology, Universitat Autònoma de Barcelona, Barcelona, Spain; Department of Surgery, Klinikum Rechts der Isar, Technische University, Munich, Germany; Institut Català d'Oncologia, IDIBELL L'Hospitalet de Llobregat, Barcelona, Spain; Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, Barcelona, Spain; Department of Surgery, Medical University of Vienna, Vienna, Austria; Department of Surgery, University of Ferrara, Ferrara, Italy; Agendia NV, Amsterdam, The Netherlands; Agendia Inc., Irvine, California, USA.
Lisette Stork-SlootsDepartments of Gastrointestinal Medical Oncology and Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Vall d'Hebron University Hospital and Institute of Oncology, Universitat Autònoma de Barcelona, Barcelona, Spain; Department of Surgery, Klinikum Rechts der Isar, Technische University, Munich, Germany; Institut Català d'Oncologia, IDIBELL L'Hospitalet de Llobregat, Barcelona, Spain; Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, Barcelona, Spain; Department of Surgery, Medical University of Vienna, Vienna, Austria; Department of Surgery, University of Ferrara, Ferrara, Italy; Agendia NV, Amsterdam, The Netherlands; Agendia Inc., Irvine, California, USA.
Dipen MaruDepartments of Gastrointestinal Medical Oncology and Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Vall d'Hebron University Hospital and Institute of Oncology, Universitat Autònoma de Barcelona, Barcelona, Spain; Department of Surgery, Klinikum Rechts der Isar, Technische University, Munich, Germany; Institut Català d'Oncologia, IDIBELL L'Hospitalet de Llobregat, Barcelona, Spain; Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, Barcelona, Spain; Department of Surgery, Medical University of Vienna, Vienna, Austria; Department of Surgery, University of Ferrara, Ferrara, Italy; Agendia NV, Amsterdam, The Netherlands; Agendia Inc., Irvine, California, USA.
Iris SimonDepartments of Gastrointestinal Medical Oncology and Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Vall d'Hebron University Hospital and Institute of Oncology, Universitat Autònoma de Barcelona, Barcelona, Spain; Department of Surgery, Klinikum Rechts der Isar, Technische University, Munich, Germany; Institut Català d'Oncologia, IDIBELL L'Hospitalet de Llobregat, Barcelona, Spain; Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, Barcelona, Spain; Department of Surgery, Medical University of Vienna, Vienna, Austria; Department of Surgery, University of Ferrara, Ferrara, Italy; Agendia NV, Amsterdam, The Netherlands; Agendia Inc., Irvine, California, USA.
Gabriel CapellàDepartments of Gastrointestinal Medical Oncology and Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Vall d'Hebron University Hospital and Institute of Oncology, Universitat Autònoma de Barcelona, Barcelona, Spain; Department of Surgery, Klinikum Rechts der Isar, Technische University, Munich, Germany; Institut Català d'Oncologia, IDIBELL L'Hospitalet de Llobregat, Barcelona, Spain; Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, Barcelona, Spain; Department of Surgery, Medical University of Vienna, Vienna, Austria; Department of Surgery, University of Ferrara, Ferrara, Italy; Agendia NV, Amsterdam, The Netherlands; Agendia Inc., Irvine, California, USA.
Ramon SalazarDepartments of Gastrointestinal Medical Oncology and Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Vall d'Hebron University Hospital and Institute of Oncology, Universitat Autònoma de Barcelona, Barcelona, Spain; Department of Surgery, Klinikum Rechts der Isar, Technische University, Munich, Germany; Institut Català d'Oncologia, IDIBELL L'Hospitalet de Llobregat, Barcelona, Spain; Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, Barcelona, Spain; Department of Surgery, Medical University of Vienna, Vienna, Austria; Department of Surgery, University of Ferrara, Ferrara, Italy; Agendia NV, Amsterdam, The Netherlands; Agendia Inc., Irvine, California, USA.
The University of Texas MD Anderson Cancer Center · USAgendia (Netherlands) · NLInstitut Català d'Oncologia · ESKlinikum rechts der Isar · DEMedical University of Vienna · ATUniversitat Autònoma de Barcelona · ESUniversitat de Barcelona · ESUniversity of Ferrara · IT
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8MSPORE in Gastrointestinal CancerP50CA095060 · NCI · UNIVERSITY OF ARIZONA · PI GERNER, EUGENE W · 2002 to 2012
$25.3MCenter for Clinical and Translational Sciences (CCTS)KL2TR000370 · NCATS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI MCPHERSON, DAVID D · 2012 to 2016
$4.3MNCATS NIH HHS KL2 TR000370NCI NIH HHS CA16672NCI NIH HHS CA95060NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA095060
Abstract
backgroundApproximately 20% of patients with stage II colorectal cancer will experience a relapse. Current clinical-pathologic stratification factors do not allow clear identification of these high-risk patients. ColoPrint (Agendia, Amsterdam, The Netherlands, http://www.agendia.com) is a gene expression classifier that distinguishes patients with low or high risk of disease relapse.
methodsColoPrint was developed using whole-genome expression data and validated in several independent validation cohorts. Stage II patients from these studies were pooled (n = 416), and ColoPrint was compared with clinical risk factors described in the National Comprehensive Cancer Network (NCCN) 2013 Guidelines for Colon Cancer. Median follow-up was 81 months. Most patients (70%) did not receive adjuvant chemotherapy. Risk of relapse (ROR) was defined as survival until first event of recurrence or death from cancer.
resultsIn the pooled stage II data set, ColoPrint identified 63% of patients as low risk with a 5-year ROR of 10%, whereas high-risk patients (37%) had a 5-year ROR of 21%, with a hazard ratio (HR) of 2.16 (p = .004). This remained significant in a multivariate model that included number of lymph nodes retrieved and microsatellite instability. In the T3 microsatellite-stable subgroup (n = 301), ColoPrint classified 59% of patients as low risk with a 5-year ROR of 9.9%. High-risk patients (31%) had a 22.4% ROR (HR: 2.41; p = .005). In contrast, the NCCN clinical high-risk factors were unable to distinguish high- and low-risk patients (15% vs. 13% ROR; p = .55).
conclusionColoPrint significantly improved prognostic accuracy independent of microsatellite status or clinical variables, facilitating the identification of patients at higher risk who might be considered for additional treatment.
Indexed as
Gene Expression ProfilingAdultAgedAged, 80 and overColorectal NeoplasmsFemaleGene Expression Regulation, NeoplasticGenomicsHumansMaleMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingNetherlandsPrognosisRisk AssessmentGene expression signatureRisk classificationRisk predictionStage II colon cancer
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.